We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





New Drugs Under Development to Treat Aggressive Prostate Cancer Could Fight COVID-19

By HospiMedica International staff writers
Posted on 17 Nov 2020
Print article
Illustration
Illustration
Two drugs under development to treat aggressive prostate cancer will now be tested to combat the deadliest response to COVID-19 infection - acute respiratory distress syndrome (ARDS).

Researchers from the Queensland University of Technology (QUT Brisbane, Australia) will test the drugs which they have been developing to fight advanced prostate cancer that could also prevent and or treat ARDS. The research team has realized their research on two hormones secreted by body fat, that modulate prostate cancer tumor growth could also have roles in driving the rapid-onset, severe lung inflammation that kills patients with serious COVID-19 disease.

The research team had been investigating two novel drugs that target fat hormones, one hormone which is pro-inflammatory, and another hormone that has an anti-inflammatory effect; each of which is involved in the progression of prostate cancer. The team had been collaborating with two US-based biotech companies to advance their research on the drugs to a Phase 1 clinical trial in prostate cancer patients.

“We have very strong data that both these drugs suppress tumor progression in advanced treatment-resistant prostate cancer and, importantly, inflammation,” said Dr. Lisa Philp. “Currently, ARDS treatment includes ventilation and antivirals but the drugs we are investigating could address the fundamental overwhelming inflammatory response by targeting the signaling hormones responsible for it.”

“We know obese people have high circulating levels of the proinflammatory hormone and thus inflammation and we have also seen that obese people are doing very poorly with COVID,” said Professor Colleen Nelson from the QUT Faculty of Health’s School of Biomedical Science. “This pro-inflammatory hormone is central to ARDS - it causes the massive inflammatory response so that it is actually your own immune response that attacks you, not the virus. We have developed a very potent drug with a North Carolina company that blocks this proinflammatory hormone from acting which we think could prevent and suppress the cytokine storm.”

Related Links:
Queensland University of Technology (QUT)

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Vibrating Mesh Nebulizer
Aerogen Solo

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.